Gaseous nitric oxide to treat antibiotic resistant bacterial and fungal lung infections in patients with cystic fibrosis: a phase I clinical study

Infection

Volumn 44, Issue 4, 2016, Pages 513-520

  Deppisch, Caroline ^a   Herrmann, Gloria ^a   Graepler Mainka, Ute ^a   Wirtz, Hubertus ^b   Heyder, Susanne ^c   Engel, Corinna ^a   Marschal, Matthias ^a   Miller, Christopher C ^d   Riethmüller, Joachim ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b UNIVERSITY OF LEIPZIG   (Germany)

^c ROBERT BOSCH GMBH   (Germany)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Antimicrobial; Cystic fibrosis; Lung infection; Nitric oxide

Indexed keywords

ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; NITRIC OXIDE; ANTIINFECTIVE AGENT;

ADULT; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ANTIFUNGAL ACTIVITY; ANTIFUNGAL RESISTANCE; ARTERIAL PRESSURE; ARTICLE; ASPERGILLUS FLAVUS; ASPERGILLUS FUMIGATUS; BACTERIAL INFECTION; BACTERIAL LOAD; CLINICAL ARTICLE; COLONY FORMING UNIT; COMMON COLD; CYSTIC FIBROSIS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ESCHERICHIA COLI; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; LOWER RESPIRATORY TRACT INFECTION; LUNG FUNCTION; LUNG INFECTION; LUNG MYCOSIS; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MYCOBACTERIUM ABSCESSUS; OPEN STUDY; OXYGEN SATURATION; PATIENT SAFETY; PHASE 1 CLINICAL TRIAL; PNEUMONIA; PSEUDOMONAS AERUGINOSA; QUALITY OF LIFE; STAPHYLOCOCCUS AUREUS; STENOTROPHOMONAS MALTOPHILIA; UPPER RESPIRATORY TRACT INFECTION; XEROSTOMIA; CLINICAL TRIAL; COMPLICATION; FEASIBILITY STUDY; MICROBIOLOGY; RESPIRATORY TRACT INFECTIONS;

ADULT; ANTI-INFECTIVE AGENTS; CYSTIC FIBROSIS; DRUG RESISTANCE, BACTERIAL; DRUG RESISTANCE, FUNGAL; FEASIBILITY STUDIES; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; MALE; NITRIC OXIDE; RESPIRATORY TRACT INFECTIONS;

EID: 84957615108     PISSN: 03008126     EISSN: 14390973     Source Type: Journal    
DOI: 10.1007/s15010-016-0879-x     Document Type: Article

References (31)

1. Rommens JM, Iannuzzi MC, Kerem BS, Drumm ML, Melmer G, Dean M, Rozmahel R, Cole JL, Kennedy D, Hidaka N. Identification of the cystic fibrosis gene: chromosome walking and jumping. Science. 1989;245:1059–65.
2. Riordan JR, Rommens JM, Kerem BS, Kerem B, Alon N, Rozmahel R, Grzelczak Z, Zielenski J, Lok S, Plavsic N, Chou JL. Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science. 1989;245:1066–73.
3. Kerem BT, Rommens JM, Buchanan JA, Markiewicz D, Cox TK, Chakravarti A, Buchwald M, Tsui LC. Identification of the cystic fibrosis gene: genetic analysis. Science. 1989;245:1073–80.
4. Ratjen F, Döring G. Cystic fibrosis. Lancet. 2003;361:681–9.
5. Döring G, Flume P, Heijerman H, Elborn JS, for the Consensus Study Group. treatment of lung infection in patients with cystic fibrosis: current and future strategies. J Cyst Fibros. 2012;11:461–79.
6. Høiby N, Ciofu O, Bjarnsholt T. Pseudomonas aeruginosa biofilms in cystic fibrosis. Future Microbiol. 2010;5:1663–74.
7. Oliver A, Canton R, Campo P, Baquero F, Blazquez J. High frequency of hypermutable Pseudomonas aeruginosa in cystic fibrosis lung infection. Science. 2000;288:1251–4.
8. Levy J. Antibiotic activity in sputum. J Pediatr. 1986;108:841–6.
9. Cox MJ, Allgaier M, Taylor B, Baek MS, Huang YJ, Daly RA, Karaoz U, Andersen GL, Brown R, Fujimura KE, Wu B, Tran D, Koff J, Kleinhenz ME, Nielson D, Brodie EL, Lynch SV. Airway microbiota and pathogen abundance in age-stratified cystic fibrosis patients. PLoS ONE. 2010;5:e11044. doi:10.1371/journal.pone.0011044.
10. Döring G, Conway SP, Heijerman HGM, Hodson ME, Høiby N, Smyth A, Touw DJ. Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: a European consensus. Eur Respir J. 2000;16:749–67.
11. Falagas ME, Bliziotis IA. Pandrug-resistant Gram-negative bacteria: the dawn of the post-antibiotic era? Int J Antimicrob Agents. 2007;6:630–6.
12. Stone A, Saiman L. Update on the epidemiology and management of Staphylococcus aureus, including methicillin-resistant Staphylococcus aureus, in patients with cystic fibrosis. Curr Opin Pulm Med. 2007;13:515–21.
13. Cystic fibrosis foundation patient registry 2010 annual data report. Bethesda, MD, USA: Cystic Fibrosis Foundation; 2011.
14. McCallum SJ, Gallagher MJ, Corkill JE, Hart CA, Ledson MJ, Walshaw MJ. Spread of an epidemic Pseudomonas aeruginosa strain from a patient with cystic fibrosis (CF) to non-CF relatives. Thorax. 2002;57:559–60.
15. Jelsbak L, Johansen HK, Frost AL, Thøgersen R, Thomsen LE, Ciofu O, Yang L, Haagensen JA, Høiby N, Molin S. Molecular epidemiology and dynamics of Pseudomonas aeruginosa populations in lungs of cystic fibrosis patients. Infect Immun. 2007;5:2214–24.
16. Moncada S, Higgs A. The l-arginine-nitric oxide pathway. N Engl J Med. 1993;329:2002–12.
17. Palmer RMJ, Ferrige AG, Moncada S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature. 1987;327:524–6.
18. DeGroote MA, Fang FC. Antimicrobial properties of nitric oxide. In: Fang FC, editor. Nitric oxide and infection. New York: Kluwer/Plenum Publishers; 1999. p. 231–47.
19. McMullin B, Chittock B, Roscoe D, Garcha H, Wang L, Miller CC. The antimicrobial effect of nitric oxide on the bacteria that cause nosocomial pneumonia in mechanically ventilated patients in the ICU. Resp Care. 2005;50:1451.
20. Grasemann H, Ratjen F. Nitric oxide and l-arginine deficiency in cystic fibrosis. Curr Pharm Des. 2012;18:726–36.
21. Miller C, Rawat M, Johnson T, Av-Gay Y. Innate protection of mycobacteria against the antimicrobial activity of nitric oxide is provided by mycothiol. Antimicrob Agents Chemother. 2007;51:3364–6.
22. Miller CC, Hergott CA, Rohan M, Arsenault-Mehta K, Doering G, Mehta S. Inhaled nitric oxide decreases the bacterial load in a rat model of Pseudomonas aeruginosa pneumonia. J Cyst Fibrosis. 2013;10:1016.
23. Miller CC, Miller M, McMullin B, Regev G, Serghides L, Kain K, Road J, Av-Gay Y. A phase I clinical study of inhaled nitric oxide in healthy adults. J Cyst Fibros. 2012;11:324–31.
24. Yoon SS, Coakley R, Lau GW, Lymar SV, Gaston B, Karabulut AC, Hennigan RF, Hwang SH, Buettner G, Schurr MJ, Mortensen JE, Burns JL, Speert D, Boucher RC, Hassett DJ. Anaerobic killing of mucoid Pseudomonas aeruginosa by acidified nitrite derivatives under cystic fibrosis airway conditions. J Clin Invest. 2006;116:436–46.
25. Fang FC. Mechanisms of nitric oxide related antimicrobial activity. J Clin Invest. 1997;99:2818–25.
26. Vazquez-Torres A, Stevanin T, Jones-Carson J, Castor M, Read RC, Fang FC. Analysis of nitric oxide-dependent antimicrobial actions in macrophages and mice. Meth Enzymol. 2008;437:521–38.
27. Ghaffari A, Miller CC, McMullin B, Ghahary A. Potential application of gaseous nitric oxide as a topical antimicrobial agent. Nitric Oxide. 2006;14:21–9.
28. Food and Drug Administration Approval of NDA 20-846 INOmax nitric oxide gas 1999.
29. Hurford WE. Nitric oxide as a bacterial agent: Is the cure worse than the disease? Respir Care. 2005;50:1428–9.
30. Regev-Shoshani G, Selvarani S, McMullin B, Road J, Av-Gay Y, Miller C. Gaseous nitric oxide reduces influenza infectivity in vitro. Nitric Oxide. 2013;31:48–53.
31. Regev-Shoshani G, Crowe A, Miller C. Nitric oxide eradicates mycelia and conidia of Trichophyton rubrum and Trichophyton mentagrophytes in-vitro. J Appl Microbiol. 2013;114:536–44.